Table 2.
MicroRNA based therapies for the treatment of human diseases and their stages of development.
| Therapeutic Names | Treatment for Human Disease | Target miRNAs | Stage of Development |
|---|---|---|---|
| Miravirsen | HCV infection | AntagomiRs targeting miR-122 | Phase II |
| RG-101 | HCV infection | AntagomiRs targeting miR-122 | On hold |
| RG-125 (AZD4076) | Nonalcoholic steatohepatitis | AntagomiRs targeting miR-103/107 | On hold |
| RGLS5040 | Cholestatic diseases | AntagomiRs targeting miR-27 | On hold |
| RG-012 | Fibrogenesis of organs associated with Alport syndrome | AntagomiRs targeting miR-21 | On hold |
| MRG-201 (Remlarsen) | Fibrotic diseases | LNA RNA mimic miR-29a | Phase I |
| MRX34 | Cancers | RNA mimic miR-34a | Phase I |
| MRG-106 (Cobomarsen) | Lymphoma and leukemia | LNA antagomiRs targeting miR-155 | Phase II |
| MRG-107 | Amyotrophic lateral sclerosis | AntagomiRs targeting miR-155 | Preclinical |
| MRG-110 | Ischemic conditions such as heart failure | Mixer of LNA and DNA antagomiR targeting miR-92 | Phase I |
| Mesomir | Malignant pleural mesothelioma | RNA mimic miR-16 | Phase II |
| ABX464 | Crohn’s disease and ulcerative colitis | Compound inducing miR-124 | Phase II |